SI-BONE, Inc. (SIBN) Fair Value 2026

SIBN · Surgical & Medical Instruments & Apparatus ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.0 /10

32 fundamental signals · 11 models active

Value Trap Risk

(—/100)

Quick Summary — As of 2026-07-14, SI-BONE, Inc. (SIBN) trades at $16.91, approximately 273% above CirclFi’s Bayesian DCF fair value of $4.54. QOC: 8.0/10. 11/13 models active.

Key Facts

Ticker
SIBN
Price
$16.91
Quality Score
8.0/10
Value Trap Risk
—/100
Models Active
11/13
Last Updated
Strength: 11 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Valuation Matrix

11 Intrinsic Value Models vs. Current Price ($16.91)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$4.54 -73.2%
Earnings Power Value
Medium Conviction
$6.28 -62.8%
CUCE Ensemble
Low Conviction
$5.50 -67.5%
First Chicago
High Conviction
$1.19 -93.0%

Unlock the Full Matrix

Access 7 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is SI-BONE, Inc. (SIBN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, SI-BONE, Inc.'s intrinsic value is estimated at $6.23. Trading at its current price of $16.91, the valuation engine raises significant caution: 10 of 11 models flag downside risk, projecting an average implied return of -63.2%. The most optimistic model, PWERM, places fair value at $17.09 (+1.0%), while ML-RIV — the most conservative — estimates $0.55 (-96.7%). This +97.8% gap reflects genuine analytical uncertainty about SI-BONE, Inc.'s intrinsic worth.

What Do the Models Say About SIBN?

11 of 13 models are currently active for SIBN. Of these, 1 model suggests upside while 10 models suggest overvaluation. The Bayesian DCF estimates SIBN's intrinsic value at $4.54, implying -73.2% downside from the current price. See which stocks rank higher →

How Does SIBN Rank in Surgical & Medical Instruments & Apparatus?

Among 117 Surgical & Medical Instruments & Apparatus stocks, SIBN ranks #20 by Quality of Company score. CirclFi's QOC score of 8.0/10 evaluates 32 fundamental signals. A score of 8.0 indicates above-average quality.

See all Most Undervalued Surgical & Medical Instruments & Apparatus Stocks →

SI-BONE, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is SIBN a Value Trap?

The Value Trap algorithm is not active for SIBN. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for SI-BONE, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, SI-BONE, Inc. scores 8.0 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +97.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SIBN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SIBN's 11 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy SI-BONE, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Surgical & Medical Instruments & Apparatus Stocks Should You Also Analyze?

8 related Surgical & Medical Instruments & Apparatus stocks with 13-model coverage

Read investment analysis: DXCM · IRMD · PODD · RMD · WST

See all Surgical & Medical Instruments & Apparatus stocks ranked →

Frequently Asked Questions About SI-BONE, Inc.

What is SI-BONE, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, SI-BONE, Inc. (SIBN) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $4.54. The Quality of Company score is 8.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SIBN overvalued or undervalued right now?

At $16.91, 1 of 11 active models suggest SIBN may be undervalued, while 10 indicate potential overvaluation. The assessment depends on which methodology best fits SI-BONE, Inc.'s business model in Surgical & Medical Instruments & Apparatus.

What does a Quality of Company score of 8.0 mean for SIBN?

SI-BONE, Inc.'s QOC of 8.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on SIBN?

CirclFi analyzes SIBN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Is SIBN a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for SIBN at this time. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on SIBN.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access